Combined breast MRI/biomarker strategies to identify aggressive biology
Combined breast MRI/biomarker strategies to identify aggressive biology
批准号:
9208242
负责人:
Ruth O'Regan
金额:
$69.86万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2021-07-31
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Triple-negative breast cancers [ER (-)/PR (-)/HER2wt (TNBC)] are highly aggressive breast cancers that frequently occur in BRCA1 mutation carriers and young women of African origin (AA). While Ashkenazi women with TNBC have a 60% incidence of germline BRCA1 mutation, less than 40% of Caucasian and only 20% of AA women with TNBC carry a germline BRCA1 mutation. We discovered a novel tumor suppressor gene, WW domain-containing oxidoreductase (WWOX) and observe that loss of WWOX activates glycolysis and glucose uptake. In this proposal, we aim to investigate the role of WWOX signaling in activating metabolism in TNBC. In preliminary data, we observe Wwox-deficient cells exhibit increased HIF1a and activity and display increased glucose uptake. WWOX deficiency is associated with enhanced glycolysis and diminished mitochondrial respiration, consistent with the 'Warburg effect'. Based on our preliminary data, we hypothesize that WWOX controls glycolytic genes' expression through regulation of HIF1a. In pilot studies, we tested for loss of WWOX expression and FLIM metabolic imaging in human breast tissue. We observe that WWOX expression is lost in 88% of TNBC, and in all AA women we tested. In these preliminary studies we observed that loss of WWOX expression correlated high glycolytic metabolic signatures in both non-cancerous tissue from high-risk and in TNBC. Taken together these studies highlight a potential role for the tumor suppressor WWOX in activating glycolysis and cellular metabolism during cancer initiation. Here we aim to test from the bench to the clinic
the hypothesis that loss of the tumor suppressor WWOX 1) in preclinical models mechanistically activates of glycolysis in metastatic TNBC via transcriptional activation HIF1a and 2) in primary and metastatic TNBC activates metabolism as measured by Fluorescence Lifetime Imaging (FLIM). Aim 1 will test whether loss of WWOX in TNBC activate glycolysis by transcriptional activation of HIF1a. Aim 2 will investigate whether loss of WWOX expression predicts increased metabolism/glycolysis during progression and metastasis of TNBC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diversity Supplement to Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
-
批准号:9462438
-
项目类别:
-
资助金额:$19.02万
-
财政年份:2015
-
负责人:Ruth O'Regan
-
依托单位:
Combined breast MRI/biomarker strategies to identify aggressive biology
-
批准号:9118941
-
项目类别:
-
资助金额:$69.5万
-
财政年份:2015
-
负责人:Ruth O'Regan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
-
批准号:82372743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈卓佳
-
依托单位:
全基因组micro-RNA种子区结合序列SNP标志体系与乳腺癌发病风险的关联及相关功能研究
-
批准号:81172762
-
项目类别:面上项目
-
资助金额:68.0万元
-
批准年份:2011
-
负责人:陈可欣
-
依托单位:
CD4+CD25+调节性T细胞对肿瘤干细胞的影响及其调控机制研究
-
批准号:81171983
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:李慧
-
依托单位:
miR-502与其靶基因SET8在乳腺癌中的功能研究
-
批准号:81071627
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:刘奔
-
依托单位:
CD44与RAS通路对乳腺癌细胞EMT过程的协同调控研究
-
批准号:81001186
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:曹文枫
-
依托单位:
DARC在基底细胞样乳腺癌中作用机制的研究
-
批准号:81001172
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:王杰
-
依托单位:
Girdin通过细胞骨架协调乳腺癌细胞增殖与移行的机制探索
-
批准号:81072172
-
项目类别:面上项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:姜平
-
依托单位:
p32在调控PKCzeta活性和乳腺癌细胞趋化运动的作用机制研究
-
批准号:81001188
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:张飞
-
依托单位:
STAT3/IDO途径参与乳腺癌髓系来源抑制细胞(MDSCs)下调T细胞免疫及相关机制探讨
-
批准号:81072159
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:于津浦
-
依托单位:
应用蛋白敲除技术降解ErbB家族的抗乳腺癌作用及其机制研究
-
批准号:30901754
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:李慧
-
依托单位: